The 5th In Vivo Cell Engineering & Gene Editing Summit returns as the leading industry meeting dedicated to advancing the next generation of in vivo delivery platforms, gene editing tools, and translational strategies that support safe, precise, and scalable genetic medicines. Designed for scientists, technical leaders, and strategic decision-makers across biopharma, this summit provides a focused forum to exchange practical insights that directly influence scientific and clinical progress.
Over three days of data-driven discussion, attendees will explore the latest advancements in lipid nanoparticle engineering, viral and nonviral vector optimization, capsid evolution, and emerging delivery technologies for targeted, efficient editing. Sessions will detail how teams are engineering payloads to enhance potency, durability, safety, and manufacturability. Speakers will also share frameworks for designing rigorous preclinical packages that address biodistribution, immunogenicity, and off-target risk early in development.
The summit places a strong focus on translational and early clinical learnings, with case studies that reveal how organizations are approaching dose selection, biomarker development, patient monitoring, and regulatory positioning. These insights provide an unfiltered look at what has worked in real programs and how teams are adjusting strategies to improve clinical readiness.
Delegates will benefit from a mix of scientific depth and strategic clarity. Whether you are building new delivery platforms, advancing editing tools, refining analytical approaches, or preparing a therapy for first-in-human studies, this meeting helps you benchmark your progress and sharpen decision-making.
Join peers who are driving the future of in vivo gene editing and cell engineering. This summit delivers the connections, evidence-based insights, and collaborative environment needed to progress transformative genetic medicines.
To learn more and register online, please click here.